Abstract
Background: High CD47 expression has been indicated to predict a poor prognosis in human malignancies. However, the prognostic significance remains inconsistent. Methods: Eligible studies were identified in PubMed, Embase, Web of Science, and the Cochrane Library prior to July, 2017. Relevant articles were screened for overall survival (OS), disease-free survival (DFS), event-free survival (EFS), progression-free survival (PFS), and clinicopathological data. Hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were pooled using Stata v.14.0 and Revman v.5.3 software, respectively. We also investigated heterogeneity, sensitivity, and publication bias for OS. Results: This meta-analysis investigated the prognostic value of CD47 expression in 38 cohorts reported in 17 articles with 7,229 cancer patients. We found that CD47 overexpression correlated with shorter OS in cancer patients (pooled HR =1.49; 95% CI: 1.36–1.62, P Conclusions: Our findings suggested CD47 could be a useful prognostic indicator in cancer patients and may be a useful therapeutic target. However, additional studies are still needed to verify the clinical value of CD47 in human malignancies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
